Treatment

Enzalutamide Improves Survival in High-Risk Prostate Cancer

In a phase 3 trial, patients with prostate cancer with high-risk biochemical recurrence showed better outcomes with enzalutamide treatments vs leuprolide monotherapy with respect to metastasis-free survival. Both...

CURATED BY: Nina Grenon,
DNP, AGCNP- BC, AOCN

Nina Grenon,

DNP, AGCNP- BC, AOCN
Dana-Farber Cancer Institute Center for Gastrointestinal Oncology

MARIPOSA-2 and FLAURA2 Trials: Breakthroughs in NSCLC Treatment

The ESMO Asia Congress 2023 highlighted two significant studies on EGFR mutations in non-small cell lung cancer (NSCLC)....

Victoria Sherry,

DNP, CRNP, ANP-BC, AOCNP
Penn Medicine Abramson Cancer Center, University of Pennsylvania School of Nursing

CURATED BY:
Victoria Sherry,
DNP, CRNP, ANP-BC, AOCNP

FDA Approval of Repotrectinib in Adult Patients Who Have Locally Advanced or Metastatic ROS1-Positive NSCLC

This article highlights the FDA approval of repotrectinib for adults with advanced ROS1-positive non-small cell lung cancer, based on the...

Victoria Sherry,

DNP, CRNP, ANP-BC, AOCNP
Penn Medicine Abramson Cancer Center, University of Pennsylvania School of Nursing

CURATED BY:
Victoria Sherry,
DNP, CRNP, ANP-BC, AOCNP

Pfizer Gains FDA Approval for BRAFTOVI® + MEKTOVI® in Treating BRAF V600E Mutant Metastatic Non-Small Cell Lung Cancer

Pfizer Inc. announced that the FDA approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for treating adult patients with metastatic non-small cell...

Victoria Sherry,

DNP, CRNP, ANP-BC, AOCNP
Penn Medicine Abramson Cancer Center, University of Pennsylvania School of Nursing

CURATED BY:
Victoria Sherry,
DNP, CRNP, ANP-BC, AOCNP

COMBO300 in COLUMBUS Study Shows Significant Improvement in Melanoma Treatment Efficacy and Tolerability Over ENCO300

A recent study reviewed the outcomes of part 1 and part 2 of the COLUMBUS study, in which patients with...

Nina Grenon,

DNP, AGCNP- BC, AOCN
Dana-Farber Cancer Institute Center for Gastrointestinal Oncology

CURATED BY:
Nina Grenon,
DNP, AGCNP- BC, AOCN

Osimertinib Shows Promise in Treating Uncommon EGFR Mutations in Stage IV Non-Small Cell Lung Cancer

Researchers of a recent study evaluated the efficacy and safety of osimertinib in patients with stage IV non-small-cell lung cancer...

Nina Grenon,

DNP, AGCNP- BC, AOCN
Dana-Farber Cancer Institute Center for Gastrointestinal Oncology

CURATED BY:
Nina Grenon,
DNP, AGCNP- BC, AOCN

Company
Contact

Partner with Us
Ambassador Program

Treatment

Enzalutamide Improves Survival in High-Risk Prostate Cancer

Nina Grenon,

MARIPOSA-2 and FLAURA2 Trials: Breakthroughs in NSCLC Treatment

Victoria Sherry,

FDA Approval of Repotrectinib in Adult Patients Who Have Locally Advanced or Metastatic ROS1-Positive NSCLC

Victoria Sherry,

Pfizer Gains FDA Approval for BRAFTOVI® + MEKTOVI® in Treating BRAF V600E Mutant Metastatic Non-Small Cell Lung Cancer

Victoria Sherry,

COMBO300 in COLUMBUS Study Shows Significant Improvement in Melanoma Treatment Efficacy and Tolerability Over ENCO300

Nina Grenon,

Osimertinib Shows Promise in Treating Uncommon EGFR Mutations in Stage IV Non-Small Cell Lung Cancer

Nina Grenon,

© 2025 Point of Care Network, LLC. All Rights Reserved.

© 2023 Point of Care Network, LLC. All Rights Reserved.

Share